M&A Deal Summary

Merck Acquires Modifi Biosciences

On October 23, 2024, Merck acquired life science company Modifi Biosciences

Acquisition Highlights
  • This is Merck’s 32nd transaction in the Life Science sector.
  • This is Merck’s 27th transaction in the United States.
  • This is Merck’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2024-10-23
Target Modifi Biosciences
Sector Life Science
Buyer(s) Merck
Deal Type Add-on Acquisition

Target

Modifi Biosciences

New Haven, Connecticut, United States
Modifi Biosciences is engaged in the development of direct DNA modification-enabled cancer therapeutics. Modifi Biosciences is based in New Haven, Connecticut.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Merck

Rahway, New Jersey, United States
Category Company
Founded 1891
Sector Life Science
Employees70,000
Revenue 60.1B USD (2023)
DESCRIPTION
Merck office in Palo Alto, California.
Merck office in Palo Alto, California.

Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.

DEAL STATS #
Overall 35 of 35
Sector (Life Science) 32 of 32
Type (Add-on Acquisition) 33 of 33
State (Connecticut) 1 of 1
Country (United States) 27 of 27
Year (2024) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-08-09 CN201

Shanghai, China

CN201 is a novel CD3xCD19-targeting T-cell-engager bispecific antibody, designed to target B cells for elimination by T cells. CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of relapsed or refractory non-Hodgkin’s lymphoma and relapsed or refractory acute lymphocytic leukemia, respectively.

Buy $700M
Mergr

Product

Company

Legal